Article
Oncology
Eugenia Miranti, Dora Y. Ho, Kyle Enriquez, Aruna K. Subramanian, Bruno C. Medeiros, David J. Epstein
Summary: This study evaluated the incidence of invasive fungal diseases (IFDs) in AML patients undergoing induction chemotherapy without antifungal prophylaxis and found that a low absolute neutrophil count was associated with an increased risk of IFD. This suggests that IFDs remain frequent in AML patients.
LEUKEMIA & LYMPHOMA
(2022)
Article
Immunology
Prithviraj Bose, David McCue, Sebastian Wurster, Nathan P. Wiederhold, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Lucia Masarova, Koichi Takahashi, Zeev Estrov, Musa Yilmaz, Naval Daver, Naveen Pemmaraju, Kiran Naqvi, Caitlin R. Rausch, Kayleigh R. Marx, Wei Qiao, Xuelin Huang, Carol A. Bivins, Sherry A. Pierce, Hagop M. Kantarjian, Dimitrios P. Kontoyiannis
Summary: In patients with newly diagnosed AML/MDS undergoing remission-induction chemotherapy, ISAV is a safe and effective alternative for antifungal prophylaxis, with excellent tolerability and minimal adverse effects such as mild to moderate elevation of liver function tests.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Medicine, Research & Experimental
Luiz Ricardo Soldi, Yasmin Nascimento Bernardes Coelho, Luiz Renato Paranhos, Marcelo Jose Barbosa Silva
Summary: Acute leukemias are difficult to treat and have a high mortality rate. Chemotherapy-induced immunosuppression increases the risk of infections, including invasive fungal infections. Antifungal prophylaxis is used in many countries to prevent these infections. This systematic review and meta-analysis examine the evidence for antifungal prophylaxis in acute leukemia patients undergoing induction chemotherapy and its impact on treatment response and mortality.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Andrew Hsu, Robert Matera, Kendra Vieira, John L. Reagan, Dimitrios Farmakiotis
Summary: In patients undergoing induction chemotherapy for acute myeloid leukemia, antifungal prophylaxis can decrease the incidence of invasive fungal infections and improve survival without significantly increasing resource utilization or toxicities. Having a dedicated inpatient malignant hematology service also contributes to improved outcomes when implementing antifungal prophylaxis policies.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Mauricette Michallet, Mohamad Sobh, Stephane Morisset, Alexandre Deloire, Emmanuel Raffoux, Stephane de Botton, Denis Caillot, Sylvain Chantepie, Stephane Girault, Celine Berthon, Sarah Bertoli, Stephane Lepretre, Thibaut Leguay, Sylvie Castaigne, Jean-Pierre Marolleau, Cecile Pautas, Jean-Valere Malfuson, Norbert Veyn, Thorsten Braun, Lauris Gastaud, Felipe Suarez, Aline Schmidt, Remy Gressin, Caroline Bonmati, Karine Celli-Lebras, Mohamed El-Hamri, Patricia Ribaud, Herve Dombret, Xavier Thomas, Anne Bergeron
Summary: This study evaluated the use of antifungal prophylaxis in patients with acute myeloblastic leukemia. The results showed that antifungal prophylaxis reduced the rate of invasive fungal infections and delayed their onset. Additionally, patients without fungal infections had a higher remission rate.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Multidisciplinary Sciences
Kwai Han Yoo, Hyeoung-Joon Kim, Yoo Hong Min, Dae-Sik Hong, Won Sik Lee, Hee-Je Kim, Ho-Jin Shin, Yong Park, Je-Hwan Lee, Hawk Kim
Summary: Age influences the biology and clinical outcomes of AML patients, with a decrease in the proportion of favorable risk patients and those receiving induction chemotherapy as age increases. The rates of achieving complete response (CR) also decrease with age, particularly in patients over 60 years old.
Article
Oncology
Gal Sharvit, Gabriel Heering, Maya Zlotnik, Drorit Merkel, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani
Summary: First remission is a crucial predictor for long-term outcomes in acute myeloid leukemia patients. It is debated whether the number of induction cycles required for remission affects long-term survival. Our findings suggest that achieving remission after two cycles of intensive chemotherapy, compared to just one cycle, is associated with significantly inferior survival but comparable leukemia-free survival.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Multidisciplinary Sciences
Thanawat Rattanathammethee, Kawin Munsamai, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Adisak Tantiworawit, Lalita Norasetthada
Summary: This study aimed to evaluate the performance of the D-index in predicting the risk of IFIs in AML patients. Retrospective analysis was conducted on adult AML patients who developed febrile neutropenia. The results showed that the D-index and c-D-index were more effective predictors of IFIs than the duration of neutropenia.
Article
Microbiology
Chiara Cattaneo, Francesco Marchesi, Irene Terrenato, Valentina Bonuomo, Nicola Stefano Fracchiolla, Mario Delia, Marianna Criscuolo, Anna Candoni, Lucia Prezioso, Davide Facchinelli, Crescenza Pasciolla, Maria Ilaria Del Principe, Michelina Dargenio, Caterina Buquicchio, Maria Enza Mitra, Francesca Farina, Erika Borlenghi, Gianpaolo Nadali, Vito Pier Gagliardi, Luana Fianchi, Mariarita Sciume, Pierantonio Menna, Alessandro Busca, Giuseppe Rossi, Livio Pagano
Summary: This study evaluated the incidence of invasive fungal diseases (IFD) in FLT3-mutated AML patients during chemotherapy + midostaurin induction and its correlation with different antifungal (AF) prophylaxis strategies. The results showed that the incidence of IFD was not affected by different AF strategies, and age was the only risk factor for IFD, while achieving complete remission after first induction was the only risk factor for survival.
Article
Hematology
Mohamed L. Sorror, Barry E. Storer, Amir T. Fathi, Andrew Brunner, Aaron T. Gerds, Mikkael A. Sekeres, Sudipto Mukherjee, Bruno C. Medeiros, Eunice S. Wang, Pankit Vachhani, Paul J. Shami, Esteban Pena, Mahmoud Elsawy, Kehinde Adekola, Selina Luger, Maria R. Baer, David Rizzieri, Tanya M. Wildes, Jamie Koprivnikar, Julie Smith, Mitchell Garrison, Kiarash Kojouri, Wendy Leisenring, Lynn Onstad, Jennifer E. Nyland, Pamela S. Becker, Jeannine S. McCune, Stephanie J. Lee, Brenda M. Sandmaier, Frederick R. Appelbaum, Elihu H. Estey
Summary: The study found that less-intensive induction therapies in older patients with AML were associated with higher mortality risks, but after adjusting for age, physician-assigned KPS, and chance of cure, mortality risks and QOL were similar. Patients receiving less-intensive therapies had shorter lengths of hospitalization. Randomized trials are needed to better assess the value of less-intensive and intensive therapies in older or medically infirm patients.
Article
Medicine, General & Internal
Iram Shireen, Sumra Komal, Abida Mateen Ansari, Lubna Meraj
Summary: The objective of this study was to determine the frequency of complete remission rate in patients with Acute Myeloid Leukemia (AML) after standard 3+7 induction therapy among different clinicopathological groups. The study found that the complete remission rate in AML patients after 3+7 induction therapy was 54%, with better outcomes observed in younger age group, male patients, and those with lower LDH and TLC levels.
PAKISTAN JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Hematology
Naama Keren-Froim, Gabriel Heering, Gal Sharvit, Maya Zlotnik, Arnon Nagler, Avichai Shimoni, Abraham Avigdor, Jonathan Canaani
Summary: This study found that standard molecular evaluation and the European LeukemiaNet (ELN) 2017 classification model can predict early mortality in patients with acute myeloid leukemia (AML) receiving intensive chemotherapy. Factors such as NPM1 gene mutation status, cytogenetic studies, and ELN 2017 risk category were found to be significant predictors of early mortality. The mortality rate during the induction phase also varied with the treatment timeframe.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Baohang Zhang, Qingguo Liu, Junfan Li, Yimin Hu, Xin Zhao, Pingping Huang, Shangzhu Li, Ying Wang
Summary: In this study, a shortened 3-day cyclophosphamide and Ara-C regimen was used, with the addition of low-dose venetoclax (VEN), and the efficacy and safety were reported. The results showed that this regimen is highly effective in newly diagnosed AML patients and the addition of VEN achieves a higher and deeper one-course remission.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Mariana Guarana, Marcio Nucci
Summary: Invasive fungal disease (IFD) is a common complication in AML patients undergoing intensive induction chemotherapy, and anti-mold prophylaxis is standard care. However, the use of antifungal prophylaxis in AML patients receiving less-intensive venetoclax-based regimens is not well established due to lower incidence and potential drug interactions and toxicities associated with azoles. This paper discusses risk factors for IFD in AML patients undergoing different treatment regimens, highlights the potential problems with azole use, and presents an approach to manage AML patients receiving venetoclax-based regimens without primary antifungal prophylaxis.
Article
Hematology
Arie Apel, Yakir Moshe, Yishai Ofran, Alexander Gural, Ofir Wolach, Chezi Ganzel, Jonathan Canaani, Miri Zektser, Adrian Duek, Galia Stemer, Ilana Hellman, May Basood, Avraham Frisch, Chiya Leibovitch, Maya Koren-Michowitz
Summary: Combination therapy of venetoclax with hypomethylating agents or low dose cytarabine has shown promising efficacy and safety in AML patients unfit for intensive therapy. The treatment resulted in high rates of complete remission, with adverse karyotype and ECOG performance status being significant predictors of outcomes. Treatment was generally well-tolerated, with tumor lysis syndrome occurring in a minority of patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Fernanda Salles Seguro, Larissa Lane Cardoso Teixeira, Lidiane Ines da Rosa, Wellington Fernandes da Silva, Luciana Nardinelli, Israel Bendit, Vanderson Rocha
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2020)
Article
Oncology
Wellington F. da Silva, Pedro Manoel Marques Garibaldi, Lidiane Ines da Rosa, Marcelo Bellesso, Diego Villa Cle, Marcia Torresan Delamain, Eduardo Magalhaes Rego, Juliana Pereira, Vanderson Rocha
Article
Oncology
Wellington F. da Silva, Ires H. B. Massaut, Rodrigo M. Bendlin, Lidiane I. Rosa, Elvira D. R. P. Velloso, Eduardo M. Rego, Vanderson Rocha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2020)
Article
Hematology
Douglas R. A. Silveira, Lynn Quek, Itamar S. Santos, Anna Corby, Juan L. Coelho-Silva, Diego A. Pereira-Martins, Grant Vallance, Benjamin Brown, Luciana Nardinelli, Wellington F. Silva, Elvira D. R. P. Velloso, Antonio R. Lucena-Araujo, Fabiola Traina, Andy Peniket, Paresh Vyas, Eduardo M. Rego, Israel Bendit, Vanderson Rocha
Article
Oncology
Douglas R. A. Silveira, Juan L. Coelho-Silva, Wellington F. Silva, Grant Vallance, Diego A. Pereira-Martins, Maria I. A. Madeira, Lorena L. Figueredo-Pontes, Elvira D. R. P. Velloso, Belinda P. Simoes, Andy Peniket, Robert Danby, Eduardo M. Rego, Paresh Vyas, Fabiola Traina, Israel Bendit, Lynn Quek, Vanderson Rocha
Summary: This study showed that AML patients in Brazil had worse outcomes compared to the UK, with higher early mortality, higher relapse rates, lower rates of HSCT, and longer wait times for HSCT. Efforts to improve AML outcomes in Brazil should focus on infection prevention and control, as well as increasing access to HSCT.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
R. S. Azevedo, C. Belli, L. Bassolli, L. Ferri, M. A. Perusini, A. Enrico, T. D. M. Pereira, W. F. S. Junior, V Buccheri, R. F. Pinheiro, S. M. Magalhaes, S. Schuster, J. B. Castelli, F. Traina, V Rocha, E. D. R. P. Velloso
Summary: This study analyzed the overall survival of patients with Myelodysplastic Syndrome (MDS) with isolated deletion 5q in South America. Age, ECOG, and bone marrow blasts at diagnosis were found to be associated with worse overall survival. Treatment with lenalidomide was the only factor that improved overall survival.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Hematology
Fernanda Rodrigues Mendes, Wellington Fernandes da Silva, Raphael da Costa Bandeira de Melo, Douglas Rafaele Almeida Silveira, Elvira Deolinda Rodrigues Pereira Velloso, Vanderson Rocha, Eduardo Magalhaes Rego
Summary: The study revealed that mortality rate during AML induction remains high, particularly in patients over 60 years. Factors such as age, cytogenetic stratification, as well as infection and inflammation markers, significantly influence induction death in AML patients.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Wellington F. Silva, Alexandre Silverio, Bruno Kosa Lino Duarte, Thais Ferraz Aguiar, Rodrigo Miguel Bendlin, Ires Hamyra Bezerra Massaut, Katia Borgia Barbosa Pagnano, Elvira D. R. P. Velloso, Vanderson Rocha, Eduardo Magalhaes Rego
Summary: This multicenter study in Brazil looked at outcomes of over 120 adults with Ph+ acute lymphoblastic leukemia (ALL). Results showed age was the only factor independently associated with overall survival, while lactate dehydrogenase levels and central nervous system disease at diagnosis were related to relapse in the cohort. Reporting such outcomes is important to advocate for expanded access to new drugs and transplantation in middle-income countries.
Article
Oncology
Rodrigo Dolphini Velasques, Wellington F. da Silva, Marcelo Bellesso, Vanderson Rocha, Juliana Pereira
Summary: This study aimed to investigate whether less intensive chemotherapy regimens could still be used in the upfront treatment of primary mediastinal B-cell lymphoma (PMBCL) in resource-constrained settings. The results showed that R-CHOP or R-CHOEP could still be safely adopted as upfront treatment for PMBCL.
JOURNAL OF ONCOLOGY
(2022)
Article
Oncology
Wellington F. da Silva, Maria Gabriella Cordeiro, Renata K. Kishimoto, Elvira Deolinda Rodrigues Pereira Velloso
HEMATOLOGY TRANSFUSION AND CELL THERAPY
(2022)
Article
Oncology
Keli Lima, Diego Antonio Pereira-Martins, Livia Bassani Lins de Miranda, Juan Luiz Coelho-Silva, Giovana da Silva Leandro, Isabel Weinhauser, Rita de Cassia Cavaglieri, Aline de Medeiros Leal, Wellington Fernandes da Silva, Ana Paula Alencar de Lima Lange, Elvira Deolinda Rodrigues Pereira Velloso, Emmanuel Griessinger, Jacobien R. Hilberink, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo Magalhaes Rego, Joao Agostinho Machado-Neto
Summary: The treatment of acute leukemia is challenging due to genetic heterogeneity and drug resistance of leukemic stem cells (LSCs). A study found that the drug THZ-P1-2, which inhibits PIP4K2s, affects mitochondrial homeostasis and autophagy in acute leukemia cells, leading to apoptosis, DNA damage, and cell differentiation. It showed synergistic effects with venetoclax. Sensitivity to THZ-P1-2 was associated with mitochondrial metabolism, cell cycle, cell-of-origin, and the TP53 pathway in primary leukemia cells.
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Fernanda Maria Santos, Jose Flavio Gomes Marin, Marcos Santos Lima, Wellington Fernandes Silva-Junior, Lucas Bassolli O. Alves, Frederico R. Moreira, Rodrigo Dolphini Velasques, Marcelo Junqueira Atanazio, Ana Carolina Arrais Maia, Carlos A. Buchpiguel, Valeria Buccheri, Vanderson Rocha
Summary: This study evaluated the prognostic value of quantitative PET analysis in newly diagnosed classical HL patients. The results showed that high TLG at baseline was associated with increased cumulative incidence of failure, while only Delta SUVmax >= 68.8 in iPET was significantly associated with progression-free survival. These findings suggest that a dynamic approach using quantitative analysis can improve prognostic assessment.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Wellington F. Silva, Dalila Cysne, Mariana Nassif Kerbauy, Iago Colturato, Ana Carolina Arrais Maia, Luciana Tucunduva, George Barros, Vergilio Rensi Colturato, Nelson Hamerschlak, Vanderson Rocha
Summary: The study on ALL patients undergoing HSCT in Brazilian centers found that the use of peripheral blood graft and haploidentical donors significantly reduced the risk of relapse, while central nervous system involvement and disease status increased the risk of relapse. Although OS and LFS were similar to literature data, NRM was higher.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Wellington F. Silva, Mariane T. Amano, Luiza L. Perruso, Maria Gabriella Cordeiro, Renata Kiyomi Kishimoto, Aline de Medeiros Leal, Luciana Nardinelli, Israel Bendit, Elvira D. R. P. Velloso, Eduardo M. Rego, Vanderson Rocha
Summary: This study on acute lymphoblastic leukemia (ALL) patients revealed the presence of Ph-like fusion genes and higher initial white blood cell count in patients with Ph-positive and Ph-like genetic alterations. The study also found a high early death rate and the impact of delays in allogeneic transplantation and unavailability of new agents on long-term survival. Measures to decrease early infection are important for improving prognosis.